BRAF and metastatic melanoma: Examples include PLX4032 (RG7204/RO5185426/Vemurafenib, Genentech), a selective inhibitor of mutant B-Raf, which was recently approved for treatment of metastatic melanoma, GSK2118436 (Dabrafenib, GlaxoSmithKline), a selective inhibitor of mutant B-Raf, and GSK1120212 (Trametinib, GlaxoSmithKline), a MEK inhibitor, which showed high response rates in patients with activating B-Raf mutations [7], [8].